<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02303119</url>
  </required_header>
  <id_info>
    <org_study_id>FLIRT</org_study_id>
    <nct_id>NCT02303119</nct_id>
  </id_info>
  <brief_title>Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)</brief_title>
  <acronym>FLIRT</acronym>
  <official_title>A Randomized Phase III Trial Evaluating Two Strategies of Rituximab Administration for the Treatment of First Line/Low Tumor Burden Follicular Lymphoma (Follicular Lymphoma IV/SC Rituximab Therapy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient will receive either one infusion of rituximab IV and seven administrations of
      rituximab SC (experimental arm) or four infusions of rituximab IV (standard arm).

      The hypothesis is that the use of rituximab by sub cutaneous route and the scheme of
      administration could:

        -  optimize rituximab exposure leading to improve response rate

        -  increase adaptative response and then improve long-term control disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2015</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>5.5 years</time_frame>
    <description>Time from randomization into the study to the first observation of documented disease progression or death due to any cause. If a subject has not progressed or died, PFS will be censored at the time of last visit with adequate assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5.5 years</time_frame>
    <description>time from the date of randomization to the date of death from any cause. Alive patients will be censored at their last follow-up date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rates</measure>
    <time_frame>M3 and M12</time_frame>
    <description>Disease response evaluation, assessment will be based on the International Workshop to Standardize Response criteria for NHL (Criteria for evaluation of response in Non-Hodgkin's lymphoma) according to Cheson 1999 (M3 and M12) and according to Cheson 2014 (M12 only).
The response rates will be described for each modality (CR, CRu, PR, SD and PD) and the Overall response rates (CR+CRu+PR) will also be described at the two time points (M3 &amp; M12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Response Rate during the study</measure>
    <time_frame>M3 and M12</time_frame>
    <description>Best disease response, assessment of response will be based on the International Workshop to Standardize Response criteria for NHL (Criteria for evaluation of response in Non-Hodgkin's lymphoma (Cheson, 1999)).
The response rates will be described for each modality (CR, CRu, PR, SD and PD) and the Overall response rates (CR+CRu+PR) will also be described</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next Anti-Lymphoma Treatment (TTNLT)</measure>
    <time_frame>5.5 years</time_frame>
    <description>time from randomization to the date of first documented administration of any new anti-lymphoma treatment (chemotherapy, radiotherapy, radio-immunotherapy, immunotherapy…). Patients continuing in response or who are lost to follow-up will be censored on their last visit date. Patients who died (due to any cause) before having received a new anti-lymphoma treatment will be included in the statistical analysis with death being counted as an event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular Response</measure>
    <time_frame>M3 and M12</time_frame>
    <description>Bcl-2-IgH rearrangement</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters of rituximab will be used to estimate individual area under the concentration curves of rituximab (AUC).</measure>
    <time_frame>5.5 years</time_frame>
    <description>The AUC will be used to describe the relationship between rituximab pharmacokinetics and clinical response (objective response, survival).</description>
  </other_outcome>
  <other_outcome>
    <measure>Causes of death</measure>
    <time_frame>5.5 years</time_frame>
    <description>classification by cause of death</description>
  </other_outcome>
  <other_outcome>
    <measure>Secondary cancers</measure>
    <time_frame>5.5 years</time_frame>
    <description>classification by type of cancer</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Am A : Rituximab IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 infusions of intravenous rituximab (375mg/m²) at Day 1, Day 8, Day 15 and D22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Rituximab SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 infusion of intravenous rituximab (375mg/m²) at Day 1, and 7 administrations of sub-cutaneous rituximab (1400mg) at Day 8, Day15, Day 22, Month 3, Month 5, Month 7 and Month 9.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab IV</intervention_name>
    <description>intra-venous, 375 mg/m²</description>
    <arm_group_label>Am A : Rituximab IV</arm_group_label>
    <arm_group_label>Arm B: Rituximab SC</arm_group_label>
    <other_name>MabThera IV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab SC</intervention_name>
    <description>sub-cutaneous, 1400 mg</description>
    <arm_group_label>Arm B: Rituximab SC</arm_group_label>
    <other_name>MabThera SC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed follicular lymphoma CD20+ grade 1, 2 and 3a by biopsy within
             4 months before signing informed consent

          -  Have a bone marrow biopsy within 4 months before the first study drug administration

          -  Have no prior therapy except surgery for diagnosis

          -  Aged 18 years or more with no upper age limit

          -  ECOG performance status 0-2

          -  Ann Arbor Stage II, III or IV

          -  Bi-dimensionally measurable disease defined by at least one single node or tumor
             lesion &gt; 1.5 cm assessed by CT scan and/or clinical examination

          -  With low-tumor burden defined as:

               -  Nodal or extra-nodal tumor mass with diameter less than 7 cm in its greater
                  diameter

               -  And involvement of less than 3 nodal or extra nodal sites with diameter greater
                  than 3 cm

               -  And absence of B symptoms

               -  And no symptomatic splenomegaly

               -  And no compression syndrome (ureteral, orbital, gastrointestinal…)

               -  And no pleural or peritoneal serous effusion

               -  And no cytopenia, with hemoglobin &gt; 10 g/dL (6.25mmol/L) and absolute neutrophil
                  count&gt; 1.5 G/L and platelets &gt; 100 G/L within 28 days before the randomization

               -  And LDH &lt; ULN within 28 days before the randomization

               -  And β2 microglobulin &lt; ULN within 28 days before the randomization

          -  Have signed an informed consent

          -  Must be covered by a social security system

        Exclusion Criteria:

          -  Grade 3b follicular lymphoma

          -  Ann Arbor Stage I

          -  Seropositive for or active viral infection with hepatitis B virus (HBV) HBs Ag
             positive HBs Ag negative, anti-HBs antibody positive and/or anti-HBc antibody positive
             and detectable viral DNA

        Note:

        Patients who are HBs Ag negative, anti-HBs positive and/or anti-HBc positive but viral DNA
        negative are eligible Patients who are seropositive due to a history of hepatitis B vaccine
        are eligible

          -  Known seropositive for, or active viral infection with hepatitis C virus (HCV)

          -  Known seropositive for, or active viral infection with Human Immunodeficiency Virus
             (HIV)

          -  Any of the following laboratory abnormalities within 28 days before the randomization:

        Total bilirubin or GGT or AST or ALT &gt; 3 ULN. Calculated creatinine clearance (Cockcroft
        and Gault formula) &lt; 60 mL /min

          -  Presence or history of CNS involvement by lymphoma

          -  Prior history of malignancies other than lymphoma (except for basal cell or squamous
             cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the
             subject has been free of the disease for ≥ 3 years

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          -  Patient with mental deficiency preventing proper understanding of the informed consent
             and the requirements of treatment.

          -  Adult under law-control

          -  Adult under tutelage

          -  Contraindication to use rituximab or known sensitivity or allergy to murine products

          -  Pregnant or lactating females.

          -  Concomitant disease requiring prolonged use of corticosteroids or corticosteroids
             administration for lymphoma within 28 days before the first study drug administration.

          -  Male and female patients of childbearing potential who cannot or do not wish to use an
             effective method of contraception, during the study treatment and for 12 months
             thereafter.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume Cartron, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Picard</last_name>
    <phone>+33 (0)4 27 01 27 13</phone>
    <email>stephanie.picard@lysarc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH de Pays d'Aix</name>
      <address>
        <city>Aix En Provence</city>
        <zip>13606</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdelaziz CHAIB, MD</last_name>
      <phone>+33 (0)4 42 33 50 46</phone>
      <email>achaib@ch-aix.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Pierre Moles Moreau, MD</last_name>
      <phone>+ 33 (0)2 41 35 44 75</phone>
      <email>mpmoles@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH d'Avignon - Hôpital Henri Duffaut</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Borhane Slama, MD</last_name>
      <phone>+ 33 (0)4 32 75 31 21</phone>
      <email>b.slama@ch-avignon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de Bayonnes</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla ARAUJO, MD</last_name>
      <phone>+33 (0)5 59 44 38 32</phone>
      <email>caraujo@ch-cotebasque.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de BLOIS</name>
      <address>
        <city>Blois</city>
        <zip>41016</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abderrazak EL YAMANI, MD</last_name>
      <phone>+33 (0)2 54 55 65 04</phone>
      <email>elyamaa@ch-blois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent LEVY, MD Ph</last_name>
      <phone>+33 (0)1 48 95 56 41</phone>
      <email>vincent.levy@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fontanet Bijou, MD</last_name>
      <phone>+ 33 (0)5 56 33 33 39</phone>
      <email>f.bijou@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Fitoussi, MD</last_name>
      <phone>+ 33 (0)5 56 43 73 54</phone>
      <email>o.fitoussi@bordeauxnord.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IHBN - CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe FRUCHART, MD</last_name>
      <phone>+33 (0)2 31 06 50 14</phone>
      <email>fruchart-c@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique du Parc</name>
      <address>
        <city>Castelnau Le Lez</city>
        <zip>34170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole EXBRAYAT, MD</last_name>
      <phone>+33 (0)4 67 34 20 28</phone>
      <email>exbrayat.carole@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Chambéry</name>
      <address>
        <city>Chambéry</city>
        <zip>73011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian-Matteo Pica, MD</last_name>
      <phone>+ 33 (0)4 79 96 51 05</phone>
      <email>gian-matteo.pica@ch-chambery.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Tournilhac, MD PhD</last_name>
      <phone>+ 33 (0)4 73 75 00 65</phone>
      <email>otournilhac@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina PRECUPANU, MD</last_name>
      <phone>+33 (0)3 89 12 41 02</phone>
      <email>cristina.precupanu@ch-colmar.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Haioun, MD PhD</last_name>
      <phone>+ 33 (0)1 49 81 20 51</phone>
      <email>corinne.haioun@hmn.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dijon - Hôpital d'Enfants</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Casasnovas, MD</last_name>
      <phone>+ 33 (0)3 80 29 50 41</phone>
      <email>olivier.casasnovas@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remi Gressin, MD</last_name>
      <phone>+ 33 (0)4 76 76 57 12</phone>
      <email>rgressin@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Départemental Vendée</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine Morineau, MD</last_name>
      <phone>+ 33 (0)2 51 44 61 73</phone>
      <email>nadine.morineau@chd-vendee.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital St Louis</name>
      <address>
        <city>La Rochelle</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel FLECK, MD</last_name>
      <phone>+33 (0)5 46 45 88 67</phone>
      <email>emmanuel.fleck@ch-larochelle.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital André Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassan Farhat, MD</last_name>
      <phone>+ 33 (0)1 39 63 89 09</phone>
      <email>hfarhat@ch-versailles.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katell Le Du</last_name>
      <phone>+ 33 (0)2 43 47 94 94</phone>
      <email>k.ledu@cjb72.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Claude Hurriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck Morschhauser, MD</last_name>
      <phone>+ 33 (0)3 20 44 60 68</phone>
      <email>franck.morschhauser@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle Nicolas Virelizier, MD</last_name>
      <phone>+ 33 (0)4 78 78 26 84</phone>
      <email>emmanuelle.nicolas@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Régis COSTELLO, MD</last_name>
      <phone>+33 (0)4 91 38 41 50</phone>
      <email>regis.costello@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Mercy</name>
      <address>
        <city>Metz</city>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe CARASSOU, MD</last_name>
      <phone>+33 (0)3 87 55 33 04</phone>
      <email>p.carassou@chr-metz-thionville.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Cartron, MD PhD</last_name>
      <phone>+ 33 (0)4 67 33 83 55</phone>
      <email>g-cartron@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Emile Muller</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Claude Eisenmann, MD</last_name>
      <phone>+ 33 (0)3 89 64 77 55</phone>
      <email>eisenmannj@ch-mulhouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Le Gouill, MD PhD</last_name>
      <phone>+ 33 (0)2 40 08 32 71</phone>
      <email>steven.legouill@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie du Gard Hématologie clinique</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agathe Rascalou Waultier, MD</last_name>
      <phone>+ 33 (0)4 66 68 32 31</phone>
      <email>agathe.WAULTIER.RASCALOU@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR de la Source</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omar BENBRAHIM, MD</last_name>
      <phone>+33 (0)2 38 51 44 44</phone>
      <email>omar.benbrahim@chr-orleans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bénédicte DEAU-FISCHER, MD</last_name>
      <phone>+33 (0)1 58 41 34 86</phone>
      <email>benedicte.deau-fischer@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Delarue, MD</last_name>
      <phone>+ 33 (0)1 44 49 54 16</phone>
      <email>richard.delarue@nck.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Jean</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Sahnes, MD</last_name>
      <phone>+ 33 (0)4 68 61 64 48</phone>
      <email>laurence.sanhes@ch-perpignan.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Lévêque - Centre François Magendie</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamal Bouabdallah, MD</last_name>
      <phone>+ 33 (0)5 57 65 65 11</phone>
      <email>krimo.bouabdallah@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Salles, MD PhD</last_name>
      <phone>+ 33 (0)4 78 86 43 02</phone>
      <email>gilles.salles@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH René Dubos</name>
      <address>
        <city>Pontoise</city>
        <zip>95300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo Gonzalez, MD</last_name>
      <phone>+ 33 (0)1 30 75 49 28</phone>
      <email>hugo.gonzalez@ch-pontoise.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy-Genevois</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Daguindau, MD</last_name>
      <phone>+ 33 (0)4 50 63 58 91</phone>
      <email>ndaguindau@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Delmer, MD PhD</last_name>
      <phone>+ 33 (0)3 26 78 36 44</phone>
      <email>adelmer@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Lamy de la Chapelle, MD PhD</last_name>
      <phone>+ 33 (0)2 99 28 93 12</phone>
      <email>thierry.lamy.de.la.chapelle@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Victor Provo</name>
      <address>
        <city>Roubaix</city>
        <zip>59100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abir FAWAZ, MD</last_name>
      <phone>+33 (0)3 20 99 32 70</phone>
      <email>abir.fawaz@ch-roubaix.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé Tilly, MD PhD</last_name>
      <phone>+ 33 (0)2 32 08 22 23</phone>
      <email>herve.tilly@chb.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Solal Celigny, MD</last_name>
      <phone>+ 33 (0)2 40 67 99 00</phone>
      <email>philippe.solal-celigny@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Mounier, MD</last_name>
      <phone>+ 33 (0)4 77 91 70 61</phone>
      <email>christiane.mounier@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Yves Le Foll</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>20000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Launay, MD</last_name>
      <phone>+ 33 (0)2 96 01 70 82</phone>
      <email>vincent.launay@ch-stbrieuc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc Matthieu Fornecker, MD</last_name>
      <phone>+ 33 (0)3 88 12 76 67</phone>
      <email>luc-matthieu.fornecker@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc Ysebaert, MD</last_name>
      <phone>+ 33 (0)5 61 77 20 78</phone>
      <email>ysebaert.loic@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Gyan, MD PhD</last_name>
      <phone>+ 33 (0)2 47 47 37 12</phone>
      <email>emmanuel.gyan@univ-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de TROYES</name>
      <address>
        <city>Troyes</city>
        <zip>10003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia ALI AMMAR, MD</last_name>
      <phone>+33 (0)3 25 49 47 21</phone>
      <email>nadia.ali-ama@ch-troyes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Tricot, MD</last_name>
      <phone>+ 33 (0)3 27 14 36 07</phone>
      <email>tricot-s@ch-valenciennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nancy - Hôpital de Brabois</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Feugier, MD PhD</last_name>
      <phone>+ 33 (0)3 83 15 32 82</phone>
      <email>p.feugier@chu-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Bretagne Atlantique</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Godmer, MD</last_name>
      <phone>+ 33 (0)2 97 01 41 45</phone>
      <email>pascal.godmer@ch-bretagne-atlantique.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2014</study_first_submitted>
  <study_first_submitted_qc>November 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LNH</keyword>
  <keyword>CD20+</keyword>
  <keyword>follicular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

